



TPE 2024 | Education *Fortify Your Future*

Industry Overview: The Path Ahead

What to Watch in 2024 & Beyond



Regulations

Flavors

Products

- FDA-CTP authorization
- MRTP

Illicit trade

Business

Products

- Flavors
- Menthol
- Enforcement

Economics

Risk Management

Innovation

Operating Environment

Legal issues

Politics

Other recreational molecules





State & local actions (bans)

5 states (MA, NJ, NY, RI, CA) & Nearly 400 localities in 12 states

FDA-CTP final rule on product

standards (menthol cigarettes &

flavored cigars)

- March 2024 (???)*
- Mitigating factors

*HHS FY 2023 Unified Regulatory Agenda: View Rule (reginfo.gov)

CTP product authorization

- No flavor other than tobacco authorized under PMTA <u>alone</u>
- High authorization standard

A little too quiet?

- Avoided trigger points to spur CTP action
- Full agenda next target?
- Acceptable off-ramp in the absence of any other flavored products?

Synthetic nicotine

Products: by the numbers

Source: ttps://www.fda.gov/tobacco-products/substantial-equivalence/marketing-orders-se



PMTA's since 2021:

278

Companies with Vape/ENDS products in-market received Marketing Denial Orders from CTP equaling millions of individual SKUs

4

- Companies (Logic, Reynolds, NJOY, & US Smokeless Tobacco CO.) received Marketing Granted Orders for non-traditional nicotine products
- Brand (Verve) was authorized for market with a characterizing flavor

SE's* since 2021:

*FDA tracking extends only to the end of FY 2022

authorization

11

40

Cigar SE submissions gained authorization

Cigarette SE submissions gained

- **144** Pipe product SE submissions gained authorization
 - 8 RYO product SE submissions gained authorization
 - **1** Hookah product SE submissions gained authorization

Regulations: MRTPs



Modified Risk Tobacco Product: what is it?		
Risk or exposure modification claim authorized to be made about the product	PMTA required as first step	Time-bound up to 5 years, then needs renewal
Proven to be a difficult process	In action, there are significant questions about its commercial viability	Only instance where a manufacturer can make a statement on risk & a product

Illicit Trade



Counterfeits, Tax Avoidance, Trade in Unauthorized Products

Multiple Pathways of Market Penetration: • DTC • DTR or DTW Inflows from Asia (flavored ENDS and counterfeits) Inflows from S. America (tax avoidance)

3 authorized ENDS brands (Logic, NJOY, Vuse) and an unknown number of provisionally authorized brands, all unflavored, cannot counterbalance against a large and lucrative market of unauthorized products.

Economics




US Cigarette Volumes 2012-2021




2012 2013 2014 2015 2016 2017 2018 2019 2020 2021


Prevailing economic conditions, especially inflation, will be a deciding factor in 2024 Nicotine Users in the U.S. (2021)



Total 18+ Population Nicotine Users (2021)




Nicotine Consumer Socioeconomic Indicators (2021)



Risk Management





Innovation



United States

Preauthorization is both a focus of and a constraint upon innovation

- Creates barriers to entry for new products
- Capital intensively of innovation vis-àvis preauthorization drive consolidation of innovation:
 - Capital access and operational scale
 - Product evolution
 - Market entry
 - Number of actors
- Mismatch of products to consumer preferences (performance & illicit concerns)


Globally

Combination of consumer driven & regulatory driven innovation

- Action on disposable products
- Heated products:
 - Different markets & consumers
- More straightforward route to market
- More licit players and products (greater opportunity)
- Similar concerns to the US:
 - Regulatory action on flavors
 - Youth issues
 - Illicit trade

Operating Environment: Legal





Operating Environment: Politics



The 2024 election will inject further uncertainty into not only the political but also regulatory process. Perhaps the effects are manifesting themselves already.



2016-2020 was an extraordinarily challenging time for the industry:

- EVALI crisis
- FDA actions
- International trade



Other molecules used as active ingredients used in adult recreational products will continue to face an uncertain road. It is highly unlikely, given the dynamics, that comprehensive policy decisions at the federal level will be forthcoming.

Whilst there is progress at other levels of government on normalization, the continued ambiguities at the federal level are likely to persist throughout the year and into 2025.

The similarities between these products and vape are striking.